SAGE Therapeutics (SAGE) Misses Q2 EPS by 6c; Readout of Phase 3 STATUS Trial in SRSE Now Expected in 1H 2017
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sage Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update
August 9, 2016 6:30 AM EDTPortfolio Expansion Underway Based on Recent Positive Data from SAGE-547 and SAGE-217
Top-line Data Readout of Phase 3 STATUS Trial in SRSE Now Expected in 1H 2017
Dosing Commenced in Expanded Phase 2 Program for SAGE-547 in Moderate and Severe Postpartum Depression
Phase 2 Initiations Planned for SAGE-217 in Essential Tremor and Postpartum Depression in 2H 2016
Proof-of-Concept Study Initiations Planned with SAGE-547 in Major Depressive Disorder and SAGE-217 in Parkinsons Disease in 2H 2016
Conference Call Today at 8:00 AM ET
... More
